Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

References

• RajkumarSVMultiple myeloma: 2011 update on diagnosis, risk-stratification, and managementAm J Hematol2011861576521181954
   PubMed Web of Science ®Google Scholar
• KumarSKDispenzieriALacyMQContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia Epub20131025
   Web of Science ®Google Scholar
• KyleRARajkumarSVMultiple myelomaBlood200811162962297218332230
   PubMed Web of Science ®Google Scholar
• BeksacMHaznedarRFiratli-TuglularTAddition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study GroupEur J Haematol2011861162220942865
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCIntergroupe Francophone du MyélomeMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trialLancet200737095941209121817920916
   PubMed Web of Science ®Google Scholar
• HulinCFaconTRodonPEfficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialJ Clin Oncol200927223664367019451428
   PubMed Web of Science ®Google Scholar
• KapoorPRajkumarSVDispenzieriAMelphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisLeukemia201125468969621233832
   PubMed Web of Science ®Google Scholar
• MateosMVRichardsonPGSchlagRBortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialJ Clin Oncol201028132259226620368561
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSCaravitaTItalian Multiple Myeloma Network, GIMEMAOral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trialLancet2006367951382583116530576
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLiberatiAMOral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialBlood200811283107311418505783
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLaroccaABortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalJ Clin Oncol201432763464024449241
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJ Clin Oncol201331444845523233713
   PubMed Web of Science ®Google Scholar
• WaageAGimsingPFayersPNordic Myeloma Study GroupMelphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myelomaBlood201011691405141220448107
   PubMed Web of Science ®Google Scholar
• WijermansPSchaafsmaMTermorshuizenFDutch-Belgium Cooperative Group HOVONPhase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 StudyJ Clin Oncol201028193160316620516439
   PubMed Web of Science ®Google Scholar
• GayFLaroccaAWijermansPComplete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsBlood2011117113025303121228328
   PubMed Web of Science ®Google Scholar
• KvamAKFayersPHjermstadMGulbrandsenNWisloffFHealth-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendationsEur J Haematol200983427928919558508
   PubMed Web of Science ®Google Scholar
• AcasterSGaugrisSVelikovaGYongKLloydAJImpact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional surveySupport Care Cancer201321259960722886429
   PubMed Web of Science ®Google Scholar
• GotayCCKawamotoCTBottomleyAEfficaceFThe prognostic significance of patient-reported outcomes in cancer clinical trialsJ Clin Oncol20082681355136318227528
   PubMed Web of Science ®Google Scholar
• VialaMBhakarALde la LogeCPatient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysisJ Clin Epidemiol200760767067917573982
   PubMed Web of Science ®Google Scholar
• WisløffFHjorthMHealth-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study GroupBr J Haematol199797129379136939
   PubMed Web of Science ®Google Scholar
• GulbrandsenNHjermstadMJWisløffFNordic Myeloma Study GroupInterpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differencesEur J Haematol200472317218014962235
   PubMed Web of Science ®Google Scholar
• ShermanACSimontonSLatifUSpohnRTricotGPsychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantationBone Marrow Transplant200433995596215034542
   PubMed Web of Science ®Google Scholar
• WisløffFEikaSHippeEMeasurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study GroupBr J Haematol19969236046138616024
   PubMed Web of Science ®Google Scholar
• GulbrandsenNWisløffFBrinchLNordic Myeloma Study GroupHealth-related quality of life in multiple myeloma patients receiving high dose chemotherapy with autologous blood stem-cell supportMed Oncol2001181657711778972
   PubMed Web of Science ®Google Scholar
• Uyl-de GrootCABuijtIGloudemansIJOssenkoppeleGJBergHPHuijgensPCHealth related quality of life in patients with multiple myeloma undergoing a double transplantationEur J Haematol200574213614315654905
   PubMed Web of Science ®Google Scholar
• WisløffFGulbrandsenNHjorthMLenhoffSFayersPQuality of life may be affected more by disease parameters and response to therapy than by haemoglobin changesEur J Haematol200575429329816146535
   PubMed Web of Science ®Google Scholar
• VerelstSGTermorshuizenFUyl-de GrootCADutch-Belgium Hemato-Oncology Cooperative Group (HOVON)Effect of thalidomide with melphalan and prednisone on health related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trialAnn Hematol201190121427143921472373
   PubMed Web of Science ®Google Scholar
• DelforgeMTerposERichardsonPGFewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaEur J Haematol201186537238421366694
   PubMed Web of Science ®Google Scholar
• FayersPBottomleyAEORTC Quality of Life Group; Quality of Life UnitQuality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of CancerEur J Cancer200238Suppl 4S125S13311858978
   PubMed Web of Science ®Google Scholar
• MateosMVOriolAMartínez-LópezJBortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trialLancet Oncol2010111093494120739218
   PubMed Web of Science ®Google Scholar
• BringhenSLaroccaARossiDEfficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood2010116234745475320807892
   PubMed Web of Science ®Google Scholar
• MateosMVOriolAMartínez-LópezJMaintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialBlood2012120132581258822889759
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• MoreauPKaramaneshtIIDomnikovaNPharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of Bortezomib in patients with relapsed multiple myelomaClin Pharmacokinet2012511282382923018466
   PubMed Web of Science ®Google Scholar
• ArnulfBPylypenkoHGrosickiSUpdated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaHaematologica201297121925192822689676
   PubMed Web of Science ®Google Scholar
• LaroccaACavalloFMagarottoVReduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of ageBlood201312221 abst 539
   Web of Science ®Google Scholar
• LammWDrach-SchauerBEderSDrachJBortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myelomaOncology201385422322724080991
   PubMed Web of Science ®Google Scholar
• SimpsonDLiangJHendersonRHannaMMerrimanEOnce weekly subcutaneous bortezomib with cyclophosphamide and dexamethasone is well tolerated and effective as initial treatment in symptomatic multiple myelomaBlood201312221 abst 4049
   Web of Science ®Google Scholar
• SidanaSFaimanBElsonPNeuropathy and efficacy of weekly subcutaneous bortezomib in myeloma and AL amyloidosisBlood201312221 abst 1975
   Web of Science ®Google Scholar
• RifkinRChenCDhandaRImpact of route of bortezomib administration on dose intensity and time to dose reduction in previously untreated patients with multiple myelomaBlood201312221 abst 1941
   Web of Science ®Google Scholar
• BarbeeMSHarveyRDLonialSSubcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferencesAnn Pharmacother20134791136114224259728
   PubMed Web of Science ®Google Scholar
• AllenPBLindsayHThamTCHow do patients with inflammatory bowel disease want their biological therapy administered?BMC Gastroenterol201010120064220
   PubMed Web of Science ®Google Scholar
• ScarpatoSAntivalleMFavalliEGRIVIERA co-authorsPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology (Oxford)201049228929419920093
   PubMed Web of Science ®Google Scholar
• MoreauPCoiteuxVHulinCProspective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myelomaHaematologica200893121908191118768528
   PubMed Web of Science ®Google Scholar
• KamimuraTMiyamotoTTakashimaSInjection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myelomaInt J Hematol201296452552722961216
   PubMed Web of Science ®Google Scholar
• KamimuraTMiyamotoTYokotaNHigher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomenEur J Haematol201390215716123240903
   PubMed Web of Science ®Google Scholar
• ObeidKMFerraraRSharmaMCutaneous lesion induced by a subcutaneous administration of bortezomibClin Lymphoma Myeloma Leuk201212428428622633164
   PubMed Web of Science ®Google Scholar